To investigate this possibility, mice bearing the MAC16 tumour and with an average weight loss of 5% were treated with the glucocorticoid receptor antagonist RU38486 (25 mg kg−1) and the effect on loss of body weight and tumour volume was determined (Figure 2). Here, NR3C1 is linked to neoplasm.